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Background: The E2 multimeric scaffold represents a powerful delivery system able to elicit robust humoral and
cellular immune responses upon systemic administrations. Here recombinant E2 scaffold displaying the third
variable loop of HIV-1 Envelope gp120 glycoprotein was administered via mucosa, and the mucosal and systemic
immune responses were analysed. To gain further insights into the molecular mechanisms that orchestrate the
immune response upon E2 vaccination, we analysed the transcriptome profile of dendritic cells (DCs) exposed to
the E2 scaffold with the aim to define a specific gene expression signature for E2-primed immune responses.
Results: The in vivo immunogenicity and the potential of E2 scaffold as a mucosal vaccine candidate were
investigated in BALB/c mice vaccinated via the intranasal route. Fecal and systemic antigen-specific IgA antibodies,
cytokine-producing CD4+ and CD8+ cells were induced assessing the immunogenicity of E2 particles via intranasal
administration. The cytokine analysis identified a mixed T-helper cell response, while the systemic antibody
response showed a prevalence of IgG1 isotype indicative of a polarized Th2-type immune response. RNA-Sequencing
analysis revealed that E2 scaffold up-regulates in DCs transcriptional regulators of the Th2-polarizing cell response,
defining a type 2 DC transcriptomic signature.
Conclusions: The current study provides experimental evidence to the possible application of E2 scaffold as antigen
delivery system for mucosal immunization and taking advantages of genome-wide approach dissects the type of
response induced by E2 particles.
Keywords: E2 scaffold, Vaccine, Mucosal immunity, Bone marrow-derived dendritic cells, RNA-Sequencing,
Transcriptome profile, Th2Background
The E2 system is a delivery vehicle in which antigenic
determinants are inserted on the surface of an icosahe-
dral scaffold formed by the acyltrasferase component
(E2 protein) of the multienzyme pyruvate dehydrogenase
(PDH) complex from Geobacillus stearothermophilus [1, 2].
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the presentation of N-terminal fused heterologous antigens.
The scaffold can be refolded in vitro to produce pure or
chimeric particles similar to virions in size and complexity,
it is able to confer high immunogenicity to the displayed
determinants, and it is suitable for vaccine formulations
[3–6]. Various protein domains, such as the HIV-1 Enve-
lope (Env) V3 loop, can be assembled into lipopolysacchar-
ide (LPS)-free E2 recombinant vaccines, and we previously
demonstrated that their systemic administrations are able
to elicit potent binding antibodies and T-cell responses inle is distributed under the terms of the Creative Commons Attribution 4.0
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rabbits [7].
A shared feature of many pathogens is that the infection
occurs or initiates at a mucosal surface. While systemic
vaccination offers protection against pathogens such as
polio and influenza viruses, induction of mucosal immun-
ity is required for effective protection against pathogens
such as HIV, human papillomavirus, herpes viruses,Vibrio
cholera and the Mycobacterium species [8–13]. Antibodies
patrolling the mucosal epithelium appear to play a crucial
role in blocking HIV-1 mucosal challenge [14]. Therefore,
it is necessary to develop adequate mucosal vaccination
protocols for this type of infection.
Understanding the immunological mechanisms of vac-
cination is of paramount importance for the rationale
design of a vaccine. Recently, the use of systems biology
approaches gave an important contribution to elucidate
the fundamental mechanisms by which the innate immune
system orchestrates protective immune responses triggered
by vaccination [15–17]. High-throughput sequencing can
be applied to explore cell transcriptome and to identify dif-
ferences in gene expression and alternative splicing. In vac-
cinology, gene expression patterns induced by priming
antigen presenting cells (APCs) could be used to predict
antigen immunogenicity and the type of T-helper cell
polarization, and/or help to select the appropriate adjuvant
to administer in the vaccine formulation.
As proof-of-concept, here we report the immunogenicity
of E2 scaffold in a model of mucosal vaccination, and show
that intranasal administration of E2-based vaccines is able
to induce mucosal and systemic immune responses.
Through RNA-Sequencing (RNA-Seq) analysis, we attempt
to identify the molecular signatures that could account
for E2-primed immune responses, and analyze the gene
expression profile of bone marrow-derived dendritic
cells (BMDCs) pulsed with E2 scaffold compared to
un-pulsed cells.
Methods
Purification of HIV-1 E2-based multimeric scaffolds
Expression and purification of E2 wild type (E2wt) and
recombinant E2 multimeric particles displaying the HIV-1
SF162 Envelope V3 loop peptide [amino acid 291–336,
reference strain HIV-HXB2; (Env(V3)-E2)], were per-
formed following previously described protocols [7, 18].
The purified 1.5MDa E2 60-mer particles were subjected
to endotoxin (LPS) removal by Triton X-114 (Sigma
Aldrich, Milan, Italy) phase separation [19] and to deter-
gent removal by using Thermo Scientific Pierce Detergent
Removal Resin (Thermo Fisher Scientific, IL, USA). The
final particles were tested for endotoxin using the Limulus
Amebocyte Lysate (LAL) Assay (QCL-1000, Lonza, Basel,
Switzerland), according to the manufacturer’s instructions
and were less than 0.05EU/ml.Antibodies, reagents and synthetic peptides
For flow cytometric analysis, fluorescein isothiocyanate
(FITC)-conjugated anti-mouse CD8 (clone 53-6.7) and
phycoerythrin (PE)-conjugated anti-mouse IFN-γ (XMG1.2)
were purchased from Biolegend (San Diego, CA). For
Intracellular Cytokine Staining (ICS) assay, the H-2d
MHC class I-restricted synthetic IGPGRAFYA(311–318)
peptide, corresponding to residues 311-318 of the HIV-1
Env V3 loop, was purchased from PRIMM srl (Naples,
Italy). For analysis of fecal IgA, serum IgA and IgG, the
HIV-1 SF162 clade B V3 peptide (PNNNTRKSITIGPGRA
FYATGD) and the V3 scrambled peptide (PNNNTRKSI
FYRGAPGITATGD) were purchased from Invitrogen
(Carlsbad, CA) and Genscript (Piscataway, NJ), respect-
ively. Mouse IL-4 and IFN-γ ELISA MAXTM Standard
SET kits were obtained from BioLegend. Mouse CD4+
T cell isolation kit was purchased from Miltenyi Biotec
(Bergisch Gladbach, Germany). For the quantitative
measurement of IgA antibodies in fecal samples, RayBio®
Mouse IgA ELISA Kit was purchased from RayBiotech,
Inc. (Norcross, GA, USA).
Mucosal vaccination with E2-based vaccines
Female BALB/c (H-2d MHC) mice, 6 to 12 week-old,
were purchased from Charles River Laboratory (Lecco,
Italy) and housed under specific pathogen free conditions
at the Animal Facility of the Institute of Food Science of
C.N.R., Avellino, Italy (accreditation no. DM.161/99).
Groups of five BALB/c mice were intranasally immunized
with 50 μg of E2wt, Env(V3)-E2, or Env(V3)-E2 with 1 μg/
mouse of cholera toxin (CT) adjuvant (Sigma Aldrich), at
weekly intervals for 7 weeks. The intranasal (i.n.) adminis-
tration was carried out by inoculating 20 μl of antigens to
the nostril. Fecal pellets were collected at weekly intervals,
weighed, homogenized at a concentration of 10 mg/ml in
1× phosphate buffered saline (PBS), 0.01 % sodium azide
(Sigma Aldrich), and centrifuged at 10,000 g for 10 min to
remove debris as previously described [20]; supernatants
were recovered and stored frozen. One week after the final
boost, mice were sacrificed to collect spleen and serum
samples.
ELISA assay for detection of IgA and IgG antibodies
Analysis of fecal IgA, serum IgA and IgG antibodies
(IgG, IgG1, and IgG2a) were performed by in house
ELISA as previously described [20] using the synthetic
HIV-1 SF162 V3 peptide, V3 scrambled peptide,
Env(V3)-E2 or E2wt proteins as antigens. Briefly, 96-well
ELISA plates (MaxiSorpTM, NUNC, NY) were precoated
with 100 μl/well of 2 μg/ml of E2 antigens or V3 syn-
thetic peptides in 1× PBS and incubated overnight at
4 °C. Plates were washed 4 times with PBS containing
0.05 % Tween-20 (Sigma Aldrich) and blocked by adding
200 μl/well of PBS containing 2 % bovin serum albumin
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the incubation, plates were washed 4 times with washing
buffer. Two-fold serial dilutions of sera (starting at 1:100
and ending to 1:12,800) and 100 μl of soluble fecal extracts
were added to the plates and incubated at RT for 2 h. All
samples were tested in duplicate. After washing, plates
were incubated with 1:2,000 dilution of peroxidase-
conjugated rabbit anti-mouse IgA, IgG, IgG1, or IgG2a
antibodies (Santa Cruz Biotechnology, Dallas, USA).
Results were expressed as absorbance values after blank
subtraction or as reciprocal endpoint titer of the last
dilution exhibiting OD450 ≥ 0.12. The highest dilution
tested was 1:128,000. Serum titers of <1:100 were con-
sidered negative and were reported in figures with an
arbitrary titer value of 1:10. Levels of total IgA anti-
bodies in soluble fecal extracts (100 μl of 10 mg/ml)
were quantified in duplicates using the RayBio® Mouse
IgA ELISA Kit, according to the manufacturer's in-
structions. The Env(V3)-specific IgA antibodies were
normalized by dividing the specific OD450 readings of
IgA by the total IgA concentration in ng/ml [21], mea-
sured in fecal samples at week 4 for each animal from
Env(V3)-E2 and Env(V3)-E2 + CT groups.
Detection of IL-4 and IFN-γ
Spleen cells were isolated from BALB/c mice mucosally
immunized with E2wt or Env(V3)-E2 administered with
CT. Splenocytes from each group were pooled and used
as antigen presenting cells (APCs). Afterwards, CD4+ T
cells were purified from pooled splenocytes using the
CD4+ T cell isolation kit. 1 × 105 CD4+ T cells were incu-
bated with 1 × 105 γ-irradiated APCs preloaded or not
with 50 μg/ml of E2wt, or Env(V3)-E2. Cells were cul-
tured overnight in 0.2 ml of RPMI 1640 (Lonza) medium
supplemented with 50 μM 2-mercaptoethanol, 1 mM
sodium pyruvate, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, and 10 % Fetal Calf Serum (FCS) (all from GIBCO,
Milan, Italy). Supernatants (0.1 ml/well) were assayed in
duplicate for detecting IL-4 and IFN-γ, using the mouse
IL-4 and IFN-γ ELISA MAXTM Standard SET kits, ac-
cording to the manufacturer's instructions.
Analysis of CD8 T-cell response
The antigen-specific CD8 T-cell response was assessed by
intracellular cytokine staining (ICS) assay on spleen cells
isolated from mice described above co-cultured in
vitro (2.5 × 106 cells/ml) for 6 days with γ-irradiated
(10,000 rad) LPS-blasts (1.25 × 106 cells/ml) prepulsed
with 10 μg/ml of MHC-I restricted V3 peptide. IFN-γ pro-
duction was evaluated on CD8+ gated T cells by FACS
(Fluorescence Activated Cell Sorter) analysis using FACS-
Canto II flow-cytometer and DIVA (Data-Interpolating
Variational Analysis) software (Becton Dickinson, Fuller-
ton, CA), as previously described by Jaworski et al. [7].BMDCs, RNA-Seq library production, sequencing and data
analysis
Bone marrow-derived dendritic cells (BMDCs) were
generated according to previously described protocols
[22]. Briefly, bone marrow cells were collected by flushing
tibias of C57BL/6 mice (Charles River Laboratory) with
complete medium (RPMI 1640, 50 μM 2-mercaptoethanol,
1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml
streptomycin, 10 % FCS). Cells were seeded in bacterio-
logical Petri dishes in complete medium supplemented with
200 U/ml of recombinant murine granulocyte-macrophage
colony stimulating factor (GM-CSF, Peprotech, NJ, USA)
for 7 days. Immature cells were harvested and incubated or
not for 1 more day with 50 μg/ml of LPS-free E2wt antigen
at a final concentration of 2.5 × 106 cells/ml. Total RNA
was extracted from untreated or E2-pulsed BMDCs using
Tri Reagent (Sigma Aldrich) according to manufacturer's
protocol. RNA integrity was assessed as described in Costa
et al. [23]. Paired-end libraries (100 x 2 bp) prepared using
TruSeq RNA Sample Preparation Kit (Illumina Inc., San
Diego, CA) were sequenced on Illumina HiSeq2000 plat-
form. About 200 million paired-end reads were sequenced.
Quality was assessed using FastQC (http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/). TopHat version
2.0.10 [24] was used to map reads on reference mouse
genome (mm9) and RefSeq mouse transcripts annotation
with default parameters. More than 95 % of sequenced
reads uniquely mapped to mm9. Such reads were used for
further analyses. Coverage files were produced using BED-
Tools and loaded on UCSC Genome Browsers to analyze
gene-specific features. Gene expression was measured
using Cufflinks 2 [25]. Cuffdiff and CummeRBund [26]
were used to identify differentially expressed genes using
normalized expression values (FPKM, Fragments Per
Kilobase of transcript and Million of mapped reads).
An arbitrary threshold of 0.05 FDR (False Discovery
Rate) and 1 FPKM in at least one condition was used
to filter out differentially expressed genes. Gene ontol-
ogy and pathway analysis were performed using DAVID
(Database for Annotation, Visualization and Integrated
Discovery) [27].
Statistics
Statistical analyses were performed using the unpaired
two-tailed Student's t-test. Differences were considered
statistically significant when P < 0.05.
Results
Dissection of fecal antibody responses after mucosal
immunization
To determine whether HIV-1 epitopes displayed on the
surface of E2 scaffold could elicit antigen-specific mucosal
immune responses, the V3 loop of HIV-1 Envelope gp120
glycoprotein was expressed as an N-terminal fusion to the
Fig. 1 Mucosal antibody responses. BALB/c mice (n = 5) were
intranasally immunized with: Env(V3)-E2 particles administered with
(triangle) or without (square) CT adjuvant. At weekly intervals fecal
pellets were collected to determine the presence of E2-binding
antibodies and Env-specific IgA. Naïve mouse group (N.I., n = 5,
diamonds) was used as control of background response. Fecal
anti-E2 and anti-V3 IgA antibodies were measured by coating in
ELISA assay (a) E2wt protein or (b) synthetic HIV-1 SF162 V3 peptide
(filled triangles or squares), and scrambled peptide (empty triangles or
squares). A representative experiment out of two is shown. Graphs
show the mean absorbance values (± S.D.) of fecal samples from mice
of each group at the indicated time points; statistical significance was
determined using the unpaired two-tailed Student's t-test, P value is
reported. (c) Specific levels of IgA antibodies to V3 peptide as defined
by ELISA OD450 readings normalized to whole IgA concentration in
soluble fecal extracts from mice immunized with Env(V3)-E2 particles
administered with (triangle) or without (square) CT adjuvant
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viously described methodologies [7]. The HIV-1 clade B
primary isolate SF162 (Tier 1) V3 portion (46 aminoacids
total) inserted into the E2 scaffold contained the epitope
(G312PGR315) recognized by the human anti-V3 mono-
clonal neutralizing antibody (NmAb) 447-52D and the
H-2d restricted CTL (cytotoxic T lymphocyte) epitope
(I311GPGRAFYA319). The resulting vaccines were non-
replicative multimeric particles formed by HIV-1 antigens
inserted on the surface of E260-mer scaffold protein, and we
evaluated their immunogenicity as mucosal vaccines in
mice. To this end, BALB/c mice of the H-2d haplotype
(n = 5 per group) were intranasally immunized with
Env(V3)-E2, administered with or without the adjuvant
cholera toxin (CT). Vaccinations were conducted weekly
for seven weeks. Fecal pellets were collected after each
immunization.
Mucosal IgA responses were measured against E2wt
(Fig. 1a), the synthetic HIV-1 SF162 V3-specific peptide,
corresponding to residues 301-322 of the V3 loop pre-
sented on the E2 surface, and V3 scrambled peptide
(Fig. 1b). Figure 1a shows the mean absorbance values
for antibodies obtained in feces against the E2 scaffold
reaching a plateau after 4 weeks of treatment with the
Env(V3)-E2 vaccines in presence or absence of CT. After
the first immunization, all vaccinated mice generated
anti-carrier E2-specific responses that were enhanced
following subsequent administrations (Fig. 1a) and sus-
tained throughout the course of the experiment. No statis-
tically significant differences (P > 0.05) in the absorbance
values of E2-binding antibodies were observed between
groups of immunized mice, suggesting that E2 scaffold
is also immunogenic at mucosal sites in the absence of
added adjuvant. Concerning V3-specific antibody re-
sponses, Env(V3)-E2 +CT group showed at week 7 signifi-
cantly higher levels of V3-binding antibodies compared to
Env(V3)-E2 group (P = 0.0051) (Fig. 1b). This difference re-
mains significant after normalization of the Env(V3)-spe-
cific IgA responses to whole IgA concentration (P = 0.0262,
Fig. 1c). Thus, in contrast to antibody responses to the E2
carrier, adjuvant was essential to induce detectable antigen-
specific mucosal immune responses.
Overall, this experiment demonstrates that intranasal
administration of E2-based vaccines is able to induce
anti-Env antigen-specific antibodies in fecal samples.
Analysis of systemic antibody and CD4 T cell responses
Since the strongest V3-specific IgA response was ob-
served following inoculation of Env(V3)-E2 administered
with adjuvant, we focused our interest on this group
(Env(V3)-E2 + CT) for additional experiments. The E2
wild type group (E2wt) was included to compare the re-
sponses generated against the carrier. We assessed the
systemic antibody response against the E2 scaffold and
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animals developed high titers (~104) of anti-carrier E2
specific IgG antibodies (Fig. 2a). Mice immunized with
Env(V3)-E2 particles developed significantly higher titers
of Env(V3)-E2 binding antibodies compared to the E2
wild type control group (Fig. 2a). To specifically detect
antibodies raised against the 447-52D core epitope we
used the V3 synthetic peptide as antigen (Fig. 2b and c),
and found that Env(V3)-E2 particles were able to elicit
serum IgG (Fig. 2b) and IgA (Fig. 2c) V3-binding anti-
bodies. These results indicate that intranasal delivery of
E2 is able to elicit mucosal and systemic antibody re-
sponses directed toward the 447-52D core epitope of the
HIV-1 V3 loop region.
In order to examine the type of immune responses in-
duced in vivo by E2 vaccination following the intranasal
route, we analyzed the isotype ratios of serum IgG1/
IgG2a and evaluated the induction of antigen-specific
CD4+ T cells in vaccinated mice.
We first determined the isotype of anti-V3 antibodies
in sera collected at the end of vaccination. Intranasal
administration of Env(V3)-E2 based vaccines induced a
preferential increase of IgG1 (Fig. 3a and c) against the
V3 peptide over the IgG2a isotype (Fig. 3b and c), sug-
gesting a polarization of CD4+ T cells toward the Th2
subset, consistent with findings previously reported by us
[5, 28]. We next evaluated whether mucosal administrationFig. 2 Systemic antibody responses. BALB/c mice (n = 5) were intranasally i
end of vaccination, sera were collected to determine binding antibody resp
(b-c) HIV-1 SF162 V3 synthetic peptide, by ELISA. Results were expressed as
control of background response. a Anti-carrier E2 and anti- Env-E2 IgG anti
serum IgA binding antibodies obtained from sera of each animal. Lines rep
two-tailed Student's t-test are reported. A representative experiment out ofof Env(V3)-E2 induced Th2 cells. To this end, we charac-
terized the type of the cellular immune response by meas-
uring cytokine production from splenic CD4+ T cells.
Env(V3)-E2 particles elicited antigen-specific CD4+ T cells
able to produce the Th2 cytokine IL-4 (Fig. 3d). However,
following the intranasal vaccination regimen, we also
detected IFN-γ production in CD4+ T cells purified
from vaccinated mice (Fig. 3e).
Analysis of V3-specific CD8 T-cell response
Since CD8+ T cells control the replication of highly
pathogenic immunodeficiency viruses [29, 30], we also
investigated the antigen-specific CD8+ T-cell response
following the intranasal route. One week after the final
boost, isolated splenocytes were analysed for IFN-γ pro-
duction after 6 days of in vitro stimulation with V3-
pulsed LPS-blasts. In Fig. 4 we reported the percentage
values of V3-specific IFN-γ producing CD8+ T cells
(Fig. 4a) and representative dot plots of ICS (Fig. 4b). In-
tranasal administration of Env(V3)-E2 particles was able
to induce V3-specific CD8+ T cells that produced IFN-γ.
Analysis of transcriptome profile of E2-pulsed BMDCs
We used genome-wide transcriptional approach to iden-
tify gene expression signatures induced in antigen present-
ing cells by E2 vaccine, to understand and elucidate the
molecular mechanisms that account for the E2-primedmmunized with Env(V3)-E2 plus CT adjuvant or E2wt particles. At the
onses against (a) E2wt (white bars), Env(V3)-E2 protein (gray bars) and
reciprocal endpoint titers. Naïve mouse group (N.I., n = 5) was used as
bodies. Mean values + S.D. are shown. b Anti-V3 IgG and c anti-V3
resent median values. P values determined using the unpaired
two is shown
Fig. 3 Isotype analysis and T helper cell responses. a-c Graphs show the reciprocal endpoint titers of anti-V3 isotypes from mice (n= 5) intranasally
immunized with Env(V3)-E2 + CT or E2wt. a IgG1 and b IgG2a serum anti-V3 antibodies. Naïve mouse group (N.I., n = 5) was used as control of
background response. c Anti-V3 IgG1 (gray bars) and IgG2a (white bars) endpoint titers for each animal from Env(V3)-E2 plus CT group. Lines
represent median values; statistical significance was determined using the unpaired two-tailed Student's t-test; P values are reported.
d Ex vivo production of IL-4 and e IFN-γ by purified CD4+ T cells isolated from mice immunized as above, in response to spleen cells pulsed
with no antigen (no ag), E2wt, or Env(V3)-E2. Cytokines were detected by ELISA assay; statistical significance was determined using the
unpaired two-tailed Student's t-test; P values are reported. A representative experiment out of two is shown
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Sequencing analysis on mouse immature BMDCs cultured
with LPS-free E2wt particles to explore the impact of E2
scaffold on the transcriptional profile of BMDCs. Compar-
ing the transcriptome of un-pulsed BMDCs with the tran-
scriptome of E2-treated cells, we observed a substantial
deregulation of gene expression after E2 treatment (more
than 5300 genes with FDR < 0.05). In particular, a sig-
nificant up-regulation was measured for 2984 genes
upon E2 stimulation (Fig. 5a). Statistically significant
molecular pathways perturbed in E2-pulsed BMDCs
were defined by mapping up-regulated genes to KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathways
using the Database for Annotation, Visualization and
Integrated Discovery [27]. Such analysis revealed that
E2 exposure triggers the up-regulation of genes associ-
ated with immune response, such as the “Chemokine
signaling” and the “Jak-STAT signaling” pathways, and
the expression levels of selected genes involved in these
pathways are illustrated in Fig. 5b. Interestingly, RNA-
Seq data revealed a significant up-regulation of genes
correlated with type-2 polarized DCs (green asterisks in
Fig. 5a and b). Among them, a significant transcriptional
activation was measured for genes encoding Janus Kinase2 (Jak2 gene), the Signal Transducer and Activator of
Transcription 5, STAT5 (Stat5a and Stat5b genes), the
transcription factor Nf-kB (Nfkb1), the Th2 chemokine
CCL17 (Ccl17 gene), the Notch ligand Jagged-1 protein
(Jag1 gene) and Interferon regulatory factor 4 (Irf4 gene).
Notably, an opposite expression trend was observed for
genes encoding proteins related to Th1 cell polarization.
In particular, interferon signaling genes such as Stat1
and Irf7, and chemokine and interleukin encoding
genes - including Cxcl10 and Il15 - were significantly
down-modulated after BMDC exposure to E2 compared
to untreated cells (red asterisks in Fig. 5a and b). Since the
expression of Irf4 has been positively correlated to a tran-
scriptional activation of Th2 polarization-related genes
[31], we investigated the expression level of these genes. In
particular, RNA-Seq analysis revealed that Itgam (integrin
alpha M), Pdcd1lg2 (programmed cell death 1 ligand 2),
and Ciita (class II, major histocompatibility complex,
transactivator) genes were up-regulated in DCs exposed
to E2. Furthermore, in E2-pulsed BMDCs, Il12b, Il6 and
other genes encoding receptors of innate immune system -
such as Nlrp3 (NOD-like receptor family, pyrin domain
containing 3), Tlr2 (toll-like receptor 2) and Il7r (interleu-
kin 7 receptor) genes - were up-regulated. In addition, the
Fig. 4 V3-specific CD8+ T-cell response. BALB/c mice (n = 3) were
intranasally immunized with Env(V3)-E2 plus CT or E2wt particles.
Isolated splenocytes were co-cultured with V3 (IGPGRAFYA311-318)
peptide-pulsed γ-irradiated LPS-blasts; after 6 days of in vitro stimulation,
effector cells were assayed for IFN-γ production by ICS. a Graph
represents the mean (± S.D.) of percentage values of V3-specific
CD8+ gated T cells secreting IFN-γ from all mice in each group. b
Representative dot plot analysis of IFN-γ ICS from a single mouse in
each group with the percentage values of IFN-γ positive cells indicated
in the upper right corner of each square. Statistical significance was
determined using the unpaired two-tailed Student's t-test; P value is
reported. A representative experiment out of two is shown
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molecule CD40 and the Notch2 signaling components
(Notch2, Rbpj, Mib1) increased when BMDCs were stimu-
lated with E2 (Fig. 5b). It should be emphasized that the
Notch2-RBPJ signaling receptor has been described to
control functional differentiation of DCs and specify a
unique CD11b+ DC subset required for efficient T cell
priming [32]. These results suggest that E2 scaffold may
activate DCs through innate immune receptor (PRRs,
pattern recognition receptors) and provide signals that
program DCs to prime Th2 cells, through the expression
of a Th2-type DC signature.
Discussion
Specific immune responses are characterized by different
patterns of cytokines produced by CD4+ T cells, an event
known as polarization of helper T cells and there can be
striking differences in the type of response preferentially
stimulated by different carriers and/or adjuvants. In thecontext of a vaccine formulation, it is important to dis-
sect the polarization induced by the E2 carrier in order
to understand how to best deliver and eventually com-
bine immunogens.
We previously described that subcutaneous administra-
tion of E2 particles expressing the Env(V3) hypervariable
region elicited a sustained immune response by inducing
both antibodies and antigen specific T cells [7]. Here we
report that mucosally administered Env(V3)-E2 were also
able to elicit mucosal and systemic V3-specific humoral
immune responses. Due to the limited sample volume
obtained from mice we were not able to assess the
neutralization activity of the antibodies induced by E2
immunization. However, it should be emphasized that
preclinical studies of HIV-1 vaccine candidates have
typically shown that neutralizing antibodies (NAbs)
with a long heavy chain complementarity-determining
region 3 (HCDR3) are found in non-human primate
and rabbit animal models, with the latter being cur-
rently the favorite model for testing candidates at elicit-
ing NAbs. We previously reported that our Env(V3)-E2
construct was able to induce autologous NAbs when
administered subcutaneously in rabbits, with a modest
level of neutralization of some Tier 1 viruses [7]. For
this reason we plan to assess in future work using larger
animal models the induction of neutralizing antibodies by
E2 mucosal immunization.
Here we also report that intranasal administration of
Env(V3)-E2 particles elicits antigen-specific splenic CD8+
and CD4+ T cells. The IgG1/IgG2a ratio in the sera and
the ability of Env-E2 specific CD4+ T cells to produce IL-4
suggest that a Th2-type of immune response is induced in
mice also after mucosal immunization. Th2-type CD4 T-
cell polarization has been reported to favor mucosal IgA
responses [33]. Indeed, we observed the presence of V3-
specific IgA in feces and anti-V3 IgG in sera of vaccinated
mice following E2 mucosal administration. Since the con-
tribution of monomeric IgA, essentially transudated serum
IgA, to total IgA in fecal samples has been previously
found negligible in comparison to the mucosally secreted
dimeric IgA (generally less than 0.1 %) [34], we can as-
sume that the IgA in feces from vaccinated mice were
mainly of the secretory type. However, we cannot exclude
the presence of monomeric IgA. In contrast to previous
results obtained by subcutaneous administration [5, 28],
here, we observed the ability of antigen-specific CD4+ T
cells to produce IFN-γ. These data indicate the presence
of Th2 and Th1-polarized T cells following mucosal
immunization in agreement with reports demonstrating a
Th1 switch in mucosally primed mice [35]. However, from
our data, we cannot exclude that the production of these
two cytokines may depend on the same cells.
Using an in vitro system, we measured the ability of
E2 scaffold to induce gene expression changes in antigen
Fig. 5 RNA-Seq analysis of E2-pulsed BMDCs. a Standard MA plot (“ratio intensity plot”) of the FPKM (Fragments Per Kilobase of transcript and
Million of mapped reads) of E2-pulsed bone marrow-derived dendritic cells (BMDCs) vs untreated cells per each RefSeq gene. The y-axis represents
the fold change (M= Log Ratio) and the x-axis the Average Intensity (A) for each gene (dot). Gray dots indicate differentially expressed (DE) genes.
b Heatmap showing the fold change in gene expression for selected DE genes in E2-pulsed BMDCs vs untreated cells. Green asterisks include Th2 and
MHC-II related genes; red asterisks include Th1-associated genes
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of BMDCs stimulated with the E2 scaffold, showing a
significant up-regulation of genes associated with Th2-
polarizing DC capability [36]. Notably, we observed a
significant up-regulation of the gene encoding the Notch
ligand Jagged 1 (encoded by Jag1). Its expression in DCs
has been previously described to support Notch-mediated
Th2 differentiation [37]. In addition, we reported the up-
regulation of Stat5 and Nfkb1, whose expression is re-
quired within DC in promoting Th2 immunity [38, 39],
and of Irf4, known to regulate the transcription of key
cytokines involved in the immune response [40]. Irf4
expression in DC has been very recently described to
play a role in the initiation of the Th2 cell response [41, 42].
Previous findings also revealed that Irf4 expression is
significantly correlated with the expression of CD11b
(encoded by Itgam), programmed death ligand-2 (encoded
by Pdcd1lg2) and MHC class II major histocompatibility
complex transactivator (encoded by Ciita) [31]. In agree-
ment with this study, we report here the up-regulation of
these genes in E2-stimulated DCs.
The results obtained from the transcriptome analysis
by RNA-Seq for E2-pulsed BMDCs confirm, and further
strengthen, our previous observations and findings. Indeed,we have reported that subcutaneous vaccination of C57BL/
6 mice with E2 polarizes the immune response towards a
high IgG1/IgG2a isotype ratio and induces IL-4 producing
CD4+ T cells, even in Th1-prone strains [28]. We also ob-
served this type of polarization when subcutaneous admin-
istration of E2 particles was performed in the absence or in
presence of various types of adjuvants, such as the strong
reactogenic CFA (Freund's Complete Adjuvant) or in
formulation suitable for human use, as alum (Allhidrogel)
or squalen-based oil in water emulsion (Addavax) [43].
However, when we administered E2 with another carrier,
namely the filamentous bacteriophage fd which we know
to prompt Th1 polarization, in a priming-boosting strat-
egy, we demonstrated a shift towards a mixed Th1/Th2
type of polarized response [28], indicating that it is also
possible to modulate the Th2-type of the immune re-
sponse induced by E2 administration.
E2 particles free of endotoxin, administered subcuta-
neously in the absence of added adjuvants, are also im-
munogenic, although the addition of adjuvants increases
the magnitude of the response [7]. However, in this case
of mucosal administration we could not detect antigen-
specific immune response in the absence of adjuvant
administration. Indeed, RNA-Seq analysis indicates that
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pathways of immune response as the chemokine and
the Jak-STAT signaling pathways. Moreover, the up-
regulated expression of Il12 and Il6 was found, while
the expression levels of genes encoding other proinflam-
matory cytokines did not increase upon E2 stimulation.
These levels of inflammatory response may explain why
E2 particles free of endotoxin are immunogenic when
administered subcutaneously in the absence of added
adjuvants. However, it is not sufficient to prime the im-
mune response in the absence of adjuvants in the case
of mucosal delivery.
We previously have reported that Env(V3)-E2 particles
were much more immunogenic when co-administered
with other systems such DNA expression vectors, encod-
ing Env proteins, delivered intradermally (via Gene gun)
in rabbits [7]. On the basis of these findings and of the
known role played by Th2 cells in activating and enhan-
cing B cell proliferation and humoral immune responses
[44], in order to increase the mucosal immune response
we plan, in future work, to test the mucosal delivery of E2
particles in combination with other strongly immunogenic
delivery systems.
Conclusions
In the current preclinical study we showed that E2 scaffold
is immunogenic when administered via mucosal route in
the presence of adjuvant and thus may represent a rele-
vant option for immunization against pathogens whose in-
fections occur or initiate at a mucosal surface. Moreover,
by using a genome-wide transcriptional approach, we
attempted to dissect the mechanisms by which DCs may
orchestrate the immune response following vaccination
with the E2 scaffold.
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